Pyoderma gangrenosum (PG) usually co-occurs with other diseases, most commonly inflammatory bowel disease (IBD), and is therefore a multidisciplinary problem. The review considers the relationship of diseases, the diagnosis of PG, topical and systemic therapy. PG often requires revision of IBD therapy. There are few randomized trials on the treatment of PG; the effectiveness of glucocorticosteroids, cyclosporine and tumor necrosis factor α inhibitors has been most proven. Reports of a positive effect of a number of biological agents and small molecules on PG make it possible to choose the therapy most indicated for the intestinal process.

Keywords: pyoderma gangrenosum, Crohn’s disease, ulcerative colitis, inflammatory bowel disease